Chest
-
Cancer Case Report Posters IISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMPURPOSE: An 80 year old female nonsmoker presented with a 20 lb weight loss and dysphagia. She had a normal colonoscopy and esophagogastroduodenoscopy. She had no risk factors for tuberculosis and no travel to Midwestern or South eastern United States. On PE she had a BMI of 24 with no palpable adenopathy and a normal exam ⋯ The following authors have nothing to disclose: Tuhina Raman, Mary IacoccaNo Product/Research Disclosure Information.
-
TransplantationSESSION TYPE: Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 12:15 PM - 01:15 PMPURPOSE: In order to identify the characteristics of late-onset non-infectious pulmonary complications (LONIPCs) in children who have undergone allogeneic hematopoietic stem cell transplantation (HSCT), we retrospectively evaluated the incidence, characteristics, and outcomes of LONIPCs in these patients. ⋯ The following authors have nothing to disclose: Jong-seo Yoon, Hwan Soo Kim, Jae Wook Lee, Yoon Hong Chun, Nack Gyun Chung, Hyun Hee Kim, Bin Cho, Hack Ki Kim, Joon Sung LeeNo Product/Research Disclosure Information.
-
Cancer Case Report Posters IISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Prostate cancer is known to metastasize to bones, lung, liver and the adrenals. Forty-six percent of patients with metastatic prostate cancer have pulmonary involvement. Of these patients, 21% have concomitant involvement of the pleura. However, isolated pleural involvement is rare, occurring in only 2.3- 5% of cases. Metastatic prostate disease is typically accompanied by elevations of serum and pleural fluid PSA levels. We are reporting the case of an elderly man with previously treated prostate cancer who presented with a left-sided pleural effusion. ⋯ The following authors have nothing to disclose: Abhay Vakil, Hineshkumar Upadhyay, Khalid Sherani, Kelly Cervellione, Mohammed BaburyNo Product/Research Disclosure Information.
-
COPD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Indacaterol is an ultra-long-acting beta-adrenoceptor agonist which needs to be taken once a day, licensed only for the treatment of chronic obstructive pulmonary disease (COPD). It is delivered as an aerosol formulation through a dry powder inhaler. A year-long, placebo-controlled trial published in July 2010 suggests indacaterol may be significantly more effective than twice-daily formoterol in improving FEV1. There were some reductions in the need for rescue medication, but these were not significantly different; nor was there any difference in the rate of exacerbation between the 2 active treatments. We looked at our data regarding the use of Indacaterol in a tertiary care set up. This is a real life experience looking at how Indacaterol influences clinical (MRC dyspnoea scale) and physiological (Spirometry) parameters and exacerbation episodes. ⋯ The following authors have nothing to disclose: Raja Dhar, Sanjit Ray ChaudhuriNo Product/Research Disclosure Information.
-
Telemedicine PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To describe the clinical trial protocol that aims to evaluate the effectiveness of telenursing on lung function in patients with heart failure (HF). ⋯ The following authors have nothing to disclose: Carolina Santos, Bárbara Sueli Moreira, Loyane Alves, Fernanda Mussi, Carolina Souza-MachadoNo Product/Research Disclosure Information.